; use of hydrolyzed infant formula 11, 12 ; and timing of complementary feeding [13] [14] [15] [16] [17] or the specific role of potential immunomodulatory nutrients, such as vitamin D, [18] [19] [20] long-chain polyunsaturated fatty acids, 21, 22 antioxidants, 23, 24 and folic acid, 25 in AD development. Data from these studies have been inconsistent, but as highlighted recently by Grimshaw et al, 26 focusing on single aspects of early infant nutrition might be an oversimplification of the complex interactions contributing to the development of food allergy. These observations could also be applied to AD.
Obesity is more common among asthmatic children, [27] [28] [29] and recent data suggest that obesity might also play a role in the development of AD. [30] [31] [32] However, these studies were primarily in school-aged children and used body mass index (BMI) as a proxy for adiposity. Association studies are very difficult to interpret because obesity itself is a multifactorial disease and AD has uncertain pathogenesis. A lack of studies in early childhood (0-2 years), the period with the highest incidence of AD, represents an area that should be further explored.
Therefore in this well-characterized birth cohort study (Cork Babies After SCOPE: Evaluating the Longitudinal Impact Using Neurological and Nutritional Endpoints [BASELINE] birth cohort study) targeted at growth, nutrition, and atopic disease outcomes, we conducted an integrated analysis of factors that have been reported to be associated with development of AD throughout the first year of life, including familial tendency, body composition, infant feeding, and nutritional and environmental exposures.
METHODS

Study design
From August 2008 to November 2011, 2137 infants were recruited to the ongoing Cork BASELINE birth cohort study. The Cork BASELINE birth cohort study is a noninterventional, single-center birth cohort; a complete cohort description was previously provided. 33 All women participating in the Screening for Pregnancy Endpoints (SCOPE) study were invited to partake in the Cork BASELINE birth cohort, and 1537 provided consent. SCOPE is a global multicenter longitudinal cohort study of low-risk primiparous women, with the main aim of developing screening tests for the major diseases of late pregnancy. [34] [35] [36] An additional 600 infants were enrolled after delivery from the postnatal wards of Cork University Maternity Hospital; however, these infants were not included in the current analysis because prospective antenatal data and umbilical cord blood were not collected.
The Cork BASELINE birth cohort study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures were approved by the Clinical Research Ethics Committee of the Cork Teaching Hospitals (ref ECM5 [9] 01/07/2008). BASELINE is registered with the National Institutes of Health Clinical Trials Registry (http://www. clinicaltrials.gov, ID: NCT01498965). SCOPE is registered at the Australian New Zealand Clinical Trials Registry (ACTRN12607000551493). Written informed consent for the Cork BASELINE birth cohort was obtained at 20 weeks' gestation or at birth.
For details on the Cork BASELINE birth cohort study stratified by infants with and without persistent AD at 6 and 12 months of age, see Table I .
Nutritional and clinical assessments
Information on study participants was gathered by using interviewer-led detailed questionnaires and clinical assessments at day 2 and at 2, 6, and 12 months. Questionnaires captured details on demography, maternal and paternal self-reported atopy (rhinitis, house dust mites, animals, latex, AD, bee/wasp, and asthma), environment during pregnancy, and the baby's early-life environment.
With respect to early infant nutrition, detailed information on feeding method (breast-fed, formula fed, or combination fed), frequency of feeds, name and brand of infant formula, solid food, feeding behavior, and provision of supplements was collected at each time point. Definitions for the current article include the following: exclusive breast-feeding, human milk only, with infants receiving no water, infant formula, or supplementary fluids; fully breast-feeding, human milk is the main source of nutrition, with infants occasionally receive infant formula or other drinks, although not on a regular basis; and any breast-feeding, infant receives any volume of human milk.
Anthropometric measures of weight, length, and abdominal circumference were measured by using standard operating procedures. Age-and sex-specific weight-for-length SD scores were calculated by using the LMS method 37 and World Health Organization growth reference data. 38 Based on the cohort-specific results, regional percentiles were calculated. BMI percentiles for weight at birth and 2 and 6 months were calculated, and cutoffs that represent the 91st and 98th percentiles were used in estimating the odds of AD. However, for abdominal circumference at day 2, percentiles that represent the 85th and 95th percentiles were created. Body composition analysis was performed at day 2 and 2 months in an infant-sized air displacement plethysmography system, the PEA POD Infant Body Composition System (COSMED USA, Concord, Calif), which was developed and validated for the assessment of infant body composition from birth to approximately 6 months of age. 39, 40 Fat mass, fat mass index, fat-free mass, and fat-free mass index were considered continuous measures of risk, but for estimating the odds of AD defined by the UK Working Party Diagnostic Criteria (UKWPDC), cutoffs that represent the 80th and 85th percentiles for these measures at day 2 and 2 months were created from participants in this study.
AD diagnosis
Possible AD was identified at 6 and 12 months by using serial allergy questionnaires obtained from the EuroPrevall study, 41 and AD was then formally diagnosed by using the UKWPDC. 42 The primary outcome in the current analysis was persistent AD, which was diagnosed if infants satisfied the UKWPDC at both 6 and 12 months. Secondary outcomes included AD at 6 months that achieved remission at 12 months and late-onset AD at 12 months. 
Biomarker analysis
Statistical analysis
Statistical analysis of the data was conducted with IBM SPSS for Windows, version 21 (2012; IBM, Armonk, NY). Data are presented by using descriptive statistics, including means with SDs, medians with interquartile ranges (IQRs) for continuous variables, and frequencies with percentages for categorical variables. For comparisons between categorical variables, x 2 or Fisher exact tests were used, whereas independent t tests or nonparametric tests were used for continuous variables depending on their distribution.
To date, no reference intervals have been established specifically for pregnancy or umbilical cord 25(OH)D concentrations, and therefore current thresholds for children and adults were used; the minimum threshold for vitamin D deficiency is a 25(OH)D concentration of less than 30 nmol/L, and 97.5% of the population requirements should be met at 50 nmol/L or greater. 45 In addition, serum 25(OH)D concentrations at 10 nmol/L increments were explored. An exploratory analysis of the various anthropometric and body composition measures was performed (weight percentiles, fat-free mass [in kilograms], fat mass [in kilograms], and fat mass index [fat mass in kilograms/length in meters squared] at day 2 and 2 months) examining the relationship with AD.
All potential risk factors for AD (hereditary, demographic, anthropometric, body composition, and environmental and nutritional exposures) were explored in univariate analyses for persistent AD (Table II) , late-onset AD (Table III) , and AD that achieved remission (Table IV) . Potential predictors of the primary outcome, persistent AD, were retained in the regression model if they were at a P value of less than .1 in the univariate analysis. On the basis of these analyses, we performed a multivariate logistic regression for persistent AD (Table V) , late-onset AD, and AD that achieved remission (Table VI) , including maternal and paternal atopy, fat mass at the 80th or greater percentile at day 2, vitamin D postnatal supplementation, and season of birth. Analyses were adjusted for multiple testing, with 5 variables included in the multivariate logistic regression; a P value of less than .01 was considered statistically significant. Results are interpreted by using this multiple testing-adjusted P value.
Results of all logistic regression models are reported as odd ratios (ORs) with 99% CIs. Interactions between the significant risk factors were explored.
Post hoc analysis was performed to explore whether increased fat mass modified the association between 25(OH)D concentration and AD; we tested the interaction between maternal and cord 25(OH)D concentrations and fat mass at the 80th percentile or greater at an a value significance level of .01.
RESULTS Participants
Maternal-infant dyads recruited through the SCOPE study (n 5 1537), with cord serum available (n 5 1050), and who attended and completed the 12-month assessment (12) 65 (11) 7 (13) .684 Smoker at 15 wk (%) 46 (7) 43 (8) 3 (6) .788à Domestic pet kept during pregnancy (%)
285 (40) 226 (39) 20 (38) . 808 25 107 (15) 86 (15) 8 (15) .991 <50 (%)
286 (40) 229 (40) 19 (36) .551 Vitamin D supplement in pregnancy (%)
335 (48) 260 (46) 29 (55) .216 Delivery, vaginal (%)
519 (73) 427 (75) 35 (75) .172 Family history of atopy § Maternal (%) 304 (43) 230 (40) 35 (66) .0003 Paternal (%)
242 (34) 179 (32) 24 (45) .043 Neonatal factors Sex, female (%) 3441 (48) 276 (48) 23 (43) .506 Season of birth, summer (%)
289 (41) 235 (41) 26 (49) .256 Birth weight (kg), mean (SD) 3.5 (0.5) 3.4 (0.5) 3.6 (0.5) .139* Fat mass, day 2
Fat mass (kg) > _80th percentile (%) 142 (20) 103 (18) 18 (34) .006 Fat mass index (kg/m 2 ) > _80th percentile (%) 142 (20) 105 (19) 16 (30 (Table I) .
Primparous women with a singleton pregnancy were recruited exclusively from the Cork region, and therefore the birth cohort is not nationally representative. Although more tertiary educated mothers were recruited than groups reported elsewhere, 46 ,47 other sociodemographic and infant feeding characteristics compared well with national reports, as previously described. 33 
Feeding practices
Breast-feeding was initiated in 71% of infants; 35% were exclusively breast-fed. At 2 months, 47% of infants were still receiving any breast milk, of whom 14% and 33% were exclusively and fully breast-fed, respectively. By 6 months, 1% were exclusively breast-fed, with 22% still receiving any breast milk in combination with infant formula, solid food, or both. Overall, 49% of infants were provided with a vitamin D-containing supplement at 6 months. Median age of complementary feeding for the cohort (n 5 709) was 19 weeks (interquartile range, 17-22 weeks), with 19% introduced to solid food before 17 weeks (early) and 6% after 26 weeks (late).
Anthropometry and body composition
Mean birth weight was 3. 
AD
At 6 and 12 months, the point prevalence of AD was 14.2% (99% CI, 10.5% to 17.8%) and 13.7% (99% CI, 10.3% to 17.6%), whereas the cumulative prevalence of AD in the first year of life was 20.5% (99% CI, 16.7% to 24.4%). The prevalence of persistent AD at 12 months was 7.5% (99% CI, 5.0% to 9.9%). The prevalence of late-onset AD and AD at 6 months that achieved remission by 12 months was 6.2% (99% CI, 4.0% to 8.6%) and 6.8% (99% CI, 4.5% to 9.4%), respectively. The prevalence of maternal (66% vs 40%) and paternal (45% vs 32%) atopic history was higher in infants with persistent AD. Infants with persistent AD had a higher fat mass of greater than the 80th percentile (27% vs 15%) compared with infants who never had AD (P < .05). Table  V) . No significant risk factor was identified for late-onset AD and AD that achieved remission (Table VI) .
Factors associated with persistent AD
Other anthropometric measures, including birth weight percentiles and abdominal circumference at day 2, were not associated with persistent AD. Fat-free mass and fat mass index at day 2 or any measure of body composition at 2 months were also not associated with persistent AD. This indicates that neonatal fat mass rather than body size at birth or during infancy is associated with the development of persistent AD. Among infants with a maternal atopic history, fat mass at day 2 remained a risk factor for persistent AD (OR, 2.71 [99% CI, 0.98-1.79], P 5 .012). The interactions between maternal atopy and fat mass at day 2 and between fat mass and maternal/cord serum 25(OH)D concentrations were not significant (all P > .05), and therefore no effect modifier was described for persistent AD.
Considering that some of the increased ORs were not statistically significant, we calculated post hoc statistical power for each nonsignificant association, as presented in Table V . For the association between paternal atopy and AD, the statistical power was 45% and 24% at the 5% and 1% significance level, respectively. For vitamin D supplementation at 6 months and AD association, the available statistical power was 6% and 18% at the 5% and 1% significance level, respectively. For the season of birth and AD association, the statistical power was 16% and 5% at the 5% and 1% significance level, respectively.
DISCUSSION
These data show for the first time that neonatal adiposity is positively associated with AD. Using a well-characterized, disease-specific, prospective birth cohort, we have shown that in our cohort a number of proposed risk factors for atopic disease, including maternal sociodemographic factors, smoking, BMI, mode of delivery, domestic pets, early infant feeding, age of complementary feeding, and vitamin D status during pregnancy and at delivery were not associated with the infant's risk of persistent AD and that maternal atopic history and infant fat mass were independently predictive of persistent AD as diagnosed by using a clinically validated assessment.
Adiposity is suggested to induce systemic inflammation, which might negatively influence the immature immune system and atopic outcomes. Although the precise link between obesity and AD remains to be elucidated, the hypothesis is plausible. Adipokine levels are reportedly altered in patients with AD with reduced levels of visfatin and adiponectin 48, 49 and increased levels of resistin and apelin. 48 Emerging evidence has demonstrated a positive association between adiposity, more recently central adiposity, and AD, although most studies have focused on school-aged children and used BMI, which is an indirect measure of adiposity. [30] [31] [32] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] Intrauterine exposure to maternal obesity 53 and gestational diabetes mellitus, 54,55 which have been linked to fetal macrosomia, might increase the risk of infant adiposity. Our data showed no association between maternal BMI or infant birth weight and AD. The independent association with fat mass at birth specifically requires further exploration.
Exclusive breast-feeding for 4 months is suggested to reduce AD risk. 10, 56 We found no association between breast-feeding and AD; however, our low prevalence of breast-feeding and very short breast-feeding duration 57 might have compromised our ability to elucidate the potential effect of breast-feeding on AD development in this cohort. The appropriate age to introduce solid food is continuously debated, with both the early and late introduction of food associated with an increased risk for atopic outcomes. 58, 59 In the present study solid food introduction, irrespective of whether concurrent with breast-feeding or before 17 or after 26 weeks, was not associated with AD development. A recent systematic review stated that there is no need to avoid introducing complementary foods beyond 4 months, irrespective of atopic heredity 57 ; our data support this statement. Clear and concise guidelines for complementary feeding are required, and the data presented in this article should be considered in future recommendations. Several studies examining vitamin D intake, supplementation, and status during pregnancy and in the immediate postnatal period have suggested associations between low vitamin D intake and status and atopic disease, including AD. 19, 20, [60] [61] [62] [63] [64] Other studies have described possible adverse or reverse J-shaped associations between vitamin D supplementation 65, 66 and/or high serum 25(OH)D concentrations 18, 67 on the infant's atopic disease risk. There is considerable heterogeneity among these studies, both from the design and analytic perspectives, as well as the validity of the clinical outcome. We observed no association between vitamin D supplementation in either the prenatal or postnatal period and AD. Neither did we detect an effect of serum 25(OH)D concentration during pregnancy or in cord blood on the infant's risk of persistent AD. 19, 20, 65, 68 A marginally significant seasonal variation was observed; however, we could not attribute this to serum 25(OH)D concentrations. Therefore an independent effect of sunlight per se on AD should be further explored. 69 The main strength of this study is its prospective design, along with the use of standardized allergy questionnaires and clinically validated outcomes, such as the UKWPDC for AD diagnosis and extremely high-quality repeated prospective data collection and analysis of body composition and vitamin D status. The main limitation of the study is that parental atopy was self-reported. Another limitation is the lack of direct measures for body composition beyond 2 months; because such measures do not exist, this is more a limitation of the study of body composition. Despite the large cohort, the study had a small number of infants with persistent AD, and several statistical analyses lacked adequate statistical power. This has likely caused the lack of significance between paternal atopy and persistent AD.
In conclusion, we have prospectively generated the first association of neonatal body composition with AD at 6 and 12 months. To date, there have been indirect observations that increased adiposity can increase the risk and severity of AD, but this has not been demonstrated directly or during the neonatal period. Future studies should determine whether impaired immune responses are exhibited early in life among infants with a high fat mass. Early identification of at-risk subjects might enhance the prediction of AD and could provide an opportunity for early preventative measures for these infants. 
